120

#7

							PATENT	
MIL RO	<b>О</b> Д 1	HE UNITED	STATES	PATENT	AND	TRADEMARK	OFFICE	
82 19				Dock	et No.	205.	5	
199	Inch applic	ation of: Bisch	ofberger et a l					
JAN	Serial No.:	08/653,034		Grou	ıp No.:	1205	L	
	Filed:	May 24, 1996		Exar	niner:	K. Weddington	JUN 16 1997	
	For: Novel Compounds and Methods for Synthesis and Therapy							
	Assistant	Assistant Commissioner for Patents						
	Washingt	on, D.C. 202	31					
	TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF FILING OR BEFORE MAILING OF FIRST OFFICE ACTION (37 CFR 1.97 (b))							
	CERTIFICATE OF MAILING  I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited on the date shown below with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.							
							osed) is being addressed to the	
		(check and complete apropriate item below);						
	x with suffi	37 CFR 1,8 (a) cient postage as s mail		or		as "Express Mail Office to Address Label No.		
	Date:	<u>May 16, 1</u>	199>		6	Robin Torres  print name of person r  Robin Goble  ure of person mai	4	

, .

## IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97 (b).

Date: 05/15/97					
Reg. No. 35,071	Mnllm				
•	SIGNATURE OF ATTORNEY				
Tel. No.: (415 ) 572-6569	Mark L. Bosse				
, ,	Type or print name of attorney				
	Gilead Sciences, Inc.				
	353 Lakeside Drive				
	P.O. Address				

Foster City, CA 94404

## PATENT



		Docket No.	205.5					
In re applic	ation of: Bischofberger et a l.							
Serial No.:	08/653,034	Group No.:	1205					
Filed:	May 24, 1996	Examiner:	K. Weddington					
For:	Novel Compounds and Methods for Synthesis and Therapy							
	Commissioner for Patents on, D.C. 20231							
INFORMATION DISCLOSURE STATEMENT (modified)								
List of Sections Forming Part of This Information Disclosure Statement.								
The following sections are being submitted for this Information Disclosure Statement:								
1. X 2. X	x Preliminary Statements x FORM PTO - 1449 (Modified)							
3. <u>x</u>	x Copies of Listed Information Items Accompanying This Statement							
CERTIFICATE OF MAILING  I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.								
Date:	May 16, 1997		Robin Torres  print name of person mailing paper)  Ram Josus  ure of person mailing paper)					

## Section 1. Preliminary statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97 (g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

## Section 3. Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Form PTO-1449 accompany this information statement.

Reg. No. 35,071

SIGNATURE OF ATTORNEY

Tel. No.: (415) 572-6569

Mark L. Bosse
Type or print name of attorney

Gilead Sciences, Inc. 353 Lakeside Drive

P.O. Address

Foster City, CA 94404